Biotechnology

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

Flare Therapeutics partners with Simplicis, moving from manual "human babysitting" to automated infrastructure to eliminate risk and scale drug discovery.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

A new partnership brings advanced, non-invasive Alzheimer's blood tests to community centers, aiming for mass early detection and reshaping diagnostics.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

French giant Efor deepens its North American footprint, acquiring CQV specialist DynamixE to target the complex cell and gene therapy manufacturing market.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

Regulatory delays in China scuttled Pulmatrix's merger with Cullgen, forcing the biotech to urgently seek new partners for its promising drug pipeline.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Asia's largest pharma show returns, showcasing China's evolution from the world's factory to a global hub of drug innovation and supply chain strategy.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.